Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...

We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Pfizer is paying $650 million in upfront cash and making a $350 million equity investment in Arvinas, with another $1.4 billion in backloaded milestone payments.

Pfizer has revealed that its much-anticipated ... Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared ...

Arvinas, Inc. (NASDAQ ... The company’s lead program, vepdegestrant (vepdeg), is being developed with Pfizer as a potential best-in-class ER-targeting backbone therapy for breast cancer treatment.

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...